Angiogenesis promoting proteins can be targeted to hinder tumor growth. To grow and multiply, tumors can source nutrients from the new blood vessels. The findings of this study is further discussed in PLOS Computational Biology journal.
"Identifying a measurement or quantity that predicts how specific tumors will respond, called a predictive biomarker, is extremely valuable to cancer research," said Stacey Finley, a USC assistant professor of Biomedical Engineering and co-author to the study. Finley, a Gordon S. Marshall Early Career Chair, is also a faculty member of the new USC Michelson Center for Convergent Bioscience.
Hope for New TB Treatment With Drugs to Block Angiogenesis
Tobin helped to develop the zebrafish as a model of Tuberculosis, and is now ready to use the system to study the blood vessels associated with granulomas.
Advertisement
‘Tumors exploit a biological process called angiogenesis, which is the formation of new blood vessels from pre-existing ones. To grow and multiply, tumors source nutrients delivered by this new vasculature. But tumor growth will slow down if proteins like vascular endothelial growth factor (VEGF) are inhibited.’
Tweet it Now
Tumors exploit a biological process called angiogenesis, which is the formation of new blood vessels from pre-existing ones. To grow and multiply, tumors source nutrients delivered by this new vasculature. But tumor growth will slow down if proteins like vascular endothelial growth factor (VEGF), an angiogenesis promoter, are waylaid.
The research team used a computational model of tumor-bearing mice (verified by published experimental data) to investigate the response to VEGF-inhibiting drugs and how this response is affected by tumor development. The model illuminated that certain properties of tumor growth help forecast whether drug therapy will thwart tumor expansion.
![Angiogenesis Factor May Promote Aging-Related Eye Conditions]( "Angiogenesis Factor May Promote Aging-Related Eye Conditions")
Increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration and cataracts.
"We found that certain parameters about the way the tumor grows could successfully and accurately predict the response to anti-angiogenic treatment that inhibits VEGF signaling in the mouse," Finley said. "Using the characteristics of the tumor's growth, we can predict how effective the anti-angiogenic therapy will be, or whether the tumor's growth will slow down, even before treatment begins."
A next step in the research includes a mathematical model to simulate a virtual population of mice randomly assigned different tumor growth parameters. The model will mimic tumor growth with and without drug therapy- and be able to predict mice who respond to drug therapy (resulting in slower tumor growth) and mice with no effect. The research team will further use experimental data to validate the model's predictions.
Source: Eurekalert
Angiogenesis Factor May Promote Aging-Related Eye Conditions
Increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration and cataracts.
Advertisement
"We found that certain parameters about the way the tumor grows could successfully and accurately predict the response to anti-angiogenic treatment that inhibits VEGF signaling in the mouse," Finley said. "Using the characteristics of the tumor's growth, we can predict how effective the anti-angiogenic therapy will be, or whether the tumor's growth will slow down, even before treatment begins."
A next step in the research includes a mathematical model to simulate a virtual population of mice randomly assigned different tumor growth parameters. The model will mimic tumor growth with and without drug therapy- and be able to predict mice who respond to drug therapy (resulting in slower tumor growth) and mice with no effect. The research team will further use experimental data to validate the model's predictions.
Source: Eurekalert
Plerixafor Blocks Pathway That Limits Anti-Angiogenesis Therapy
New FDA approved drug, plerixafor, which is a CRCX4 inhibitor, reduces resistance to anti-angiogenesis treatment by blocking VEGF-signaling pathway.
Advertisement
 How Anti-Angiogenesis Treatment Would Help Eliminate a TumorDeciphering and targeting mechanisms involved in resistance to anti-angiogenic therapy is critical to realizing the potential of the promising cancer therapy. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
More affected relatives, higher lung cancer risk; participants with affected mothers or siblings faced increased risk.
Colorectal cancer can be lowered by up to 7% by increasing dietary consumption of folate rich foods like spinach, broccoli or taking folate supplements.
The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.